Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
News|Articles|October 25, 2023
Daily Dose: Real-World Use of Cabotegravir for HIV PrEP
Author(s)Sydney Jennings
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on findings presented at IDWeek 2023, held October 11-15 in Boston, MA.
The study
Researchers conducted the study to assess real-world utilization and adherence to cabotegravir for PrEP in an outpatient community-based clinic network in the US. They retrospectively reviewed electronic medical records from the CAN Community Health Network encompassing 26 outpatient clinics in 6 US states. Their objective was to identify HIV-negative individuals who received a prescription or injection for cabotegravir for PrEP between December 2021 and April 2023. Demographic data collected included age, race, ethnicity, sex assigned at birth, gender identity, and sexual orientation.
Researchers focused on 2 distinct groups: Those who received ≥1 cabotegravir injections following a prescription, and those who were prescribed but did not receive any cabotegravir injections.
Findings
The study cohort consisted of 293 HIV-negative individuals (median age, 36 years) prescribed cabotegravir for PrEP.
Among the cohort, 155 (52.9%) participants received ≥1 cabotegravir injections. Among those who initiated cabotegravir for PrEP, 126 (81.3%) demonstrated PrEP persistence, and there were no reported cases of HIV seroconversion. Moreover, the discontinuation rate was 29 (18.7%) in this group.
The primary reasons for discontinuation and switching back to oral PrEP were insurance coverage gaps or cost of copay (7 cases), side effects (6 cases), and conflicts with work schedules (2 cases). In 1 case, the reason for discontinuation was not documented.
Authors' comment
"Individuals prescribed cabotegravir for PrEP reflected a diverse population. However, only 52.9% of prescriptions for cabotegravir for PrEP resulted in at least one injection administered indicating limitations in use and access to injectable [cabotegravir] for PrEP.”
Click here for more details.
Advertisement
Related to this article
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: In ARIC, menopause before age 40 was linked to higher CVD and CHD risk, with insulin resistance mediating about 19% of the association.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
2
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
3
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
4
More Frequent Physical Activity Linked to Fewer Perimenopause Symptoms in Global Study
5